Wockhardt plans to launch antibiotic Zaynich in early FY26

Mumbai: Wockhardt said that research and trials for the antibiotic Zaynich are advancing well, with plans for an early launch in FY26. Habil Khorakiwala, founder chairman of the city-based company, informed reporters that Zaynich holds a market potential of USD 25 billion.

He added that the company has invested over USD 500 million in research, resulting in six successful developments, including Zaynich, currently progressing through various stages of development and marketing.

Zaynich has been granted a susceptibility breakpoint of 64 mg per litre for around 10 gram negative pathogens showing high resistance rates by the American Clinical and Laboratory Standards Institute, according to a statement.
According to PTI, he said the company expects the final approvals from the Indian regulators to launch the antibiotic by the end of FY25 and will soon be launching it commercially after that.
For the developed markets as well, the company expects approvals to come in similar timelines or maybe with some lag, Khorakiwala said, outlining the commercial strategies.
In India, the company plans to sell the antibiotic at a tenth of the price in developed markets, and will primarily be targetting pneumonia patients, he said.
In the developed markets, it will be looking for partners willing to establish networks to sell the antibiotic, he said.
Khorakiwala said that antibiotic resistance levels are as high as 60 per cent locally and at an elevated 35 per cent globally which makes it a decent opportunity.
The antibiotic is showing efficacy in both treatment and safety in the trials, he claimed.
The company used USD 25 million from a recent Rs 480 crore equity capital raise towards the research and development of Zaynich, while Rs 100 crore was utilised to reduce the debt, an official said.
The external debt stands at about Rs 900 crore, of which Rs 500 crore is for working capital purposes, Khorakiwala said, stressing that it is comfortable from a liquidity standpoint.
Apart from this, the company has also borrowed Rs 1,000 crore from the promoter Khorakiwala family, he said, adding that the family is comfortable and not in a hurry for repayments, especially given the business opportunity it sees.

Powered by WPeMatico

ONGC opens two 100-bed hospitals at Baltal, Chandanwari

New Delhi: In a move aimed to bolster healthcare infrastructure in Jammu and Kashmir, Oil and Natural Gas Corporation (ONGC) has constructed permanent 100-bed hospitals at Baltal in Ganderbal district and Chandanwari in Anantnag district. 

Oil and Natural Gas Corporation (ONGC) has partnered with the Department of Health and Medical Education, Government of Jammu and Kashmir.

As part of its Corporate Social Responsibility (CSR) initiative, ONGC has constructed permanent hospitals in Baltal, Ganderbal district, and Chandanwari, Anantnag district. Each hospital is equipped with 100 beds, lodging facilities for medical staff, and intensive care units, functioning as Primary Health Centres to provide essential medical services to local communities, according to a statement issued by the central government undertaking.

Also Read:Union Minister Puri inaugurates ONGC-backed 300-Bed Multi-Speciality Hospital in Assam

According to an ANI report, “Each of these hospitals is equipped with 100 beds, lodging facilities for medical staff, and intensive care units that will serve as Primary Health Centres and provide essential medical services to the local communities,” the ONGC added in the statement.

In addition to enhancing local healthcare infrastructure, these hospitals will also cater to pilgrims during the Amarnath Yatra. This move replaces temporary medical facilities, addressing recurring costs and logistical challenges annually.

The PSU said that the initiative highlights its commitment to sustainable development and improved public health services, representing a significant step towards better healthcare accessibility and continuous medical support for local populations.

Upon completion, the J&K Health Department will manage the operation and maintenance of these hospitals, ensuring lasting benefits for both pilgrims and residents.

CSR projects are voluntary contributions made by companies for the betterment of society. Under this, the companies integrate social and other useful concerns in their business operations for the betterment of their stakeholders and society in general, news agency ANI reported.

However, section 135 of the Companies Act, 2013 mandates that companies that have either a net worth of more than Rs.500 crore, a turnover of more than Rs.1000 crore or a net profit of more than Rs.5 crore should contribute through the CSR.

The company fulfilling the above criteria should spend at least 2 per cent of its average net profits made during the immediately preceding three financial years.

Also Read:Tacrolimus an alternative to IV cyclophosphamide as initial therapy for Lupus Nephritis

Powered by WPeMatico